Company news
Crossject SA news in 2025
Crossject SA's news releases, calls and decks from 2025, newest first.
CROSSJECT completes €5 million financing with Vatel Capital
November 14, 2025
CROSSJECT presents its financial results and key highlights for the first half of 2025
September 24, 2025
CROSSJECT Secures Additional BARDA Funding for the Progressive Developmental and FDA Authorization of the ZEPIZURE® (ZENEO® Midazolam)
September 22, 2025
CROSSJECT remains engaged during the summer break
August 4, 2025
CROSSJECT announces a successful capital increase of €5.7 million following full exercise of the extension clause
June 24, 2025
CROSSJECT advances on the development of ZEPIZURE Junior, its solution for epilepsy crises in children
June 12, 2025
CROSSJECT advances on the development of ZEPIZURE® Junior, its solution for epilepsy crises in children
June 11, 2025
Launch of a capital increase with preferential subscription rights for nearly 5 million euros
June 4, 2025
Maxim Group initiates the coverage of the CROSSJECT share with a BUY recommendation and a target price of €4.00
June 3, 2025
CROSSJECT implements new manufacturing module to scale-up the ZENEO® Factory ‘s versatility and capacity in anticipation of full product pipeline deployment
May 27, 2025
CROSSJECT prepares for the launch of a capital increase with preferential subscription rights of around 5 million euros in preparation for commercial and production activities linked to EUA approval
May 20, 2025
CROSSJECT’s ZENEO® needle-free autoinjector consistently matches depth of traditional intramuscular injections and exceeds the standards needle length of currently utilized auto-injectors
May 15, 2025
CROSSJECT provides updates on the EUA filing of ZEPIZURE®
May 7, 2025
Decks in 2025
- Shareholder Meeting (June 2025)
Shareholder meeting · 41 slides · June 2025
- Investor Presentation (January 2025)
Investor deck · 34 slides · January 2025